Beyond statin therapy: a review of the management of residual risk in diabetes mellitus.
AffiliationDepartment of Endocrinology, St Columcille's Hospital, Loughlinstown, Co. Dublin, Ireland.
Drug Therapy, Combination
Fatty Acids, Omega-3
Hydroxymethylglutaryl-CoA Reductase Inhibitors
MetadataShow full item record
CitationBeyond statin therapy: a review of the management of residual risk in diabetes mellitus. 2010, 103 (9):357-62 J R Soc Med
JournalJournal of the Royal Society of Medicine
AbstractTotal cholesterol and low-density lipoprotein (LDL) cholesterol exhibit an independent, strong, continuous correlation with cardiovascular events. The effectiveness of hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) in the treatment and prevention of atherosclerosis is well-established. However, despite the lowering of LDL targets and the increased use of statins, patients with type 2 diabetes mellitus (DM) continue to experience a higher proportion of adverse coronary artery disease events. This is as a result of an atherogenic dyslipidaemia, characterized by low levels of high-density lipoprotein and elevated plasma triglyceride concentrations, often with high levels of cholesterol-rich remnant particles. This article will review dyslipidaemia and its role in DM, and will discuss available treatment modalities that address residual cardiovascular risk in this disease.